Irvine, Calif., October 12, 2021 — Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and diagnostic testing that enables precision medicine through early disease detection, proudly announced today the appointment of Ann Sabahat, CPA MST as the new Chief Financial Officer.
Ms. Sabahat is no stranger to the CFO role, having held the key position at several private and public companies including most recently Karat Packaging (NASDAQ: KRT), where she helped to steer the company through a successful IPO raising more than $70 million dollars in proceeds. Ms. Sabahat has nearly three decades of experience as a highly versatile finance executive specializing in multiple areas including strategic planning, revenue cycle management and regulatory compliance. She has been a licensed CPA since 1997 and earned her Master of Science in Taxation from Golden Gate University. She also holds a Bachelor’s Degree in Accounting and Finance from California State University – Fullerton.
“We could not be more excited to have Ann as part of our leadership team,” commented Emylee Thai, CEO and Founder of Artemis DNA. “Her experience will bring invaluable perspective to key decisions as we continue to grow and revolutionize the field of genetics in pursuit of our mission to Improve the overall health of the population, one family at a time.”
Artemis DNA has been growing at a rapid pace since it launched in 2019. The firm was founded by Emylee Thai, a serial entrepreneur with a proven history of success who was motivated to start the company by a passion to make innovative, affordable and actionable healthcare solutions accessible to all.
ABOUT ARTEMIS DNA
Artemis DNA is a full service, Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited, high-complexity clinical diagnostic laboratory company that provides proprietary Next Generation Sequencing (NGS) genetic testing and diagnostic laboratory services for a wide variety of medical specialties, including cardiology, oncology, immunology, neurology, reproductive health and pharmacogenomics.
Artemis DNA’s testing enhances the delivery of “personalized medicine” by assessing a patient’s own genetic makeup and clinical characteristics which allows for informed decision making in prevention and treatment choices. Artemis DNA also provides pre- and post-testing genetic education and counseling services, as well as conducting research and development to discover and develop additional novel diagnostic services. Artemis DNA is headquartered in Irvine, California. For more information, visit https://www.artemisdna.com.
ARTEMIS DNA CONTACT
Emylee Thai (Founder and CEO)
Phone: (888) 88DNA88, Extension 8